Orchard Therapeutics to Present at Investor Conferences in March
February 26, 2020 07:00 ET | Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global leader in gene therapy, today announced that members of the management team will present at the...
Orchard Therapeutics to Webcast Conference Call of 2019 Financial Results
February 20, 2020 07:00 ET | Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will host a conference call and live webcast...
Orchard Therapeutics Announces Presentation of Clinical Data from Neurometabolic Franchise at 16th Annual WORLD Symposium
February 10, 2020 07:00 ET | Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced upcoming presentations from its neurometabolic franchise at...
Orchard Therapeutics Appoints Industry Veteran Steven Altschuler, M.D. to its Board of Directors
February 03, 2020 07:00 ET | Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Feb. 03, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced the appointment of Steven Altschuler, M.D., to its board of...
Orchard Therapeutics Announces FDA Granted Orphan Drug Designation for OTL-102 for the Treatment of X-linked Chronic Granulomatous Disease (X-CGD)
January 29, 2020 07:00 ET | Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Jan. 29, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that it has received orphan drug designation from the U.S....
Orchard Therapeutics Highlights 2020 Strategic Priorities
January 13, 2020 07:00 ET | Orchard Therapeutics (Europe) Limited
Commercial Preparations on Track for Potential 2020 EU Launch of OTL-200 for Metachromatic Leukodystrophy (MLD) with U.S. Regulatory Filing Expected Late 2020 / Early 2021  Initiation of Rolling U.S....
Orchard Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
January 06, 2020 07:00 ET | Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with...
Orchard Therapeutics Showcases Clinical Data at the 61st American Society of Hematology Annual Meeting
December 08, 2019 07:00 ET | Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Dec. 08, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with...
Orchard Therapeutics Announces the Filing and Validation of Marketing Authorization Application by European Medicines Agency for OTL-200 for the Treatment of Metachromatic Leukodystrophy
December 02, 2019 07:00 ET | Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with...
European Medicines Agency Grants Orchard Therapeutics Accelerated Assessment of OTL-200 for Patients with Metachromatic Leukodystrophy
November 18, 2019 07:00 ET | Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with...